A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Most nucleoside anticancer drugs are ineffective against p53-deficient or mutated cancers, limiting their clinical use.
• p53-deficient cancers, such as prostate cancer, often exhibit resistance to conventional therapies.
• Mitogen-activated protein kinase-activated protein kinase-2 (MK2) plays a critical role in DNA damage response and cell cycle regulation in p53-deficient cells.

Purpose of the Study:

• To evaluate the efficacy of 2 '-fluoro-4 '-seleno-ara-C (F-Se-Ara-C) against p53-deficient prostate cancer.
• To investigate the mechanism of action of F-Se-Ara-C, specifically its targeting of the synthetic lethal interaction between p53 and MK2.
• To assess the potential of F-Se-Ara-C as a therapeutic agent for p53-deficient cancers.

Main Methods:

• In vitro and in vivo studies using the p53-deficient prostate cancer cell line PC-3.
• Assessment of F-Se-Ara-C's effect on MK2 activation and downstream signaling pathways.
• Combination therapy studies with F-Se-Ara-C and cabozantinib.

Main Results:

• F-Se-Ara-C demonstrated potent antitumor activity against p53-deficient prostate cancer cells.
• F-Se-Ara-C effectively inhibited MK2 activation, leading to apoptosis in p53-deficient cancer cells.
• Combination of F-Se-Ara-C with cabozantinib resulted in synergistic antitumor effects.

Conclusions:

• F-Se-Ara-C is a promising new anticancer drug candidate for p53-deficient cancers.
• Targeting the synthetic lethal interaction between p53 and MK2 offers a novel therapeutic strategy.
• F-Se-Ara-C has the potential to overcome apoptotic resistance in p53-deficient tumors.